Advitech To Market Psoriasis Supplement in The U.S.
Quebec-based Advitech said today it has reached an agreement with US company PhotoMedex to market and distribute its whey-derived psoriasis supplement in the US.The Canadian biotech firm has recently signed a deal for the product, called Dermylex, to reach the French market and said it expected further distribution to follow on quickly.
PhotoMedex, which sells products for skin health through its own sales force directly to dermatologists, cosmetic surgeons, and spas, intends to trial the product during the first quarter of 2006 in selected locations. If the market develops well, it will roll-out the product in all its sales locations in the United States in the second half of the year.
Although a dietary supplement, Advitech is targeting pharmaceutical distributors to increase awareness of its product. Last year a phase 2 clinical trial of the active ingredient, XP-828L, confirmed the efficacy and safety profile of the product for patients with mild to moderate psoriasis.
Renaud Beauchesne, chief executive of Advitech, said PhotoMedex's sales organization and access to dermatologists would allow the product to be positioned very well in the important US market.
Prior to a nationwide roll-out Advitech will sign over exclusive rights to PhotoMedex to market products using Dermylex in specific US market segments.
The contract will extend over several years, and will provide for certain minimum level of purchase of products to be negotiated between PhotoMedex and Advitech. Other terms and conditions of the Agreement were not disclosed.
PhotoMedex, which sells products for skin health through its own sales force directly to dermatologists, cosmetic surgeons, and spas, intends to trial the product during the first quarter of 2006 in selected locations. If the market develops well, it will roll-out the product in all its sales locations in the United States in the second half of the year.
Although a dietary supplement, Advitech is targeting pharmaceutical distributors to increase awareness of its product. Last year a phase 2 clinical trial of the active ingredient, XP-828L, confirmed the efficacy and safety profile of the product for patients with mild to moderate psoriasis.
Renaud Beauchesne, chief executive of Advitech, said PhotoMedex's sales organization and access to dermatologists would allow the product to be positioned very well in the important US market.
Prior to a nationwide roll-out Advitech will sign over exclusive rights to PhotoMedex to market products using Dermylex in specific US market segments.
The contract will extend over several years, and will provide for certain minimum level of purchase of products to be negotiated between PhotoMedex and Advitech. Other terms and conditions of the Agreement were not disclosed.
posted by Nick Riley @ 10:49 AM
<< Home